PACTR202112842892883尚未招募3 期
Open-label access to dolutegravir for HIV-1 infected children and adolescents completing IMPAACT Studies P1093 and P2019.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 Year(s) 至 5 Year(s)（—）
- 性别
- All
入选标准
- •Subjects must have completed participation in one of the following parent studies, for the duration noted:
- •P1093 parent study through at least Week 180
- •P2019 parent study through at least Week 48
- •Virological control at screening:
- •a) Subjects in parent study P1093 must have virological control defined as HIV-
- •1 RNA <400 c/mL at their penultimate visit (on or after the Week 180 visit). b) Subjects in parent study P2019 must have virological control defined as HIV-
- •1 RNA <200 c/mL at their penultimate visit (on or after Week 36).
- •If the penultimate P1093 or P2019 visit (on or after Week 180 for P1093; on
- •or after Week 36 for P2019) indicates the possibility of virologic failure, a single retest can be completed in the parent study.
- •–Results of the retest must be obtained and confirmed prior to the Day 1 visit (the Day 1 visit overlaps with the final visit in each parent study).
- •–If the retest indicates virologic control is present as noted above, eligibility is confirmed as long as the participant meets all other entry criteria.
- •–Adherence issues should be addressed, and viral suppression must be confirmed prior to Day 1.
- •Evidence of continued benefit from IP during the subject’s participation in the parent study (P1093 or P2019).
- •–At screening, Investigators will submit a clinical summary verifying evidence of continued benefit from IP during the subject’s participation in the parent study (P1093 or P2019).
- •–The summary will be submitted via the PPD ePIP system to the Study Medical Monitor who will review and confirm if the inclusion criterion has been met.
- •–Confirmation from the Study Medical Monitor is required to meet this eligibility criterion
- •4. Males and Females
- •All subjects who are engaging in sexual activity should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male
排除标准
- •Confirmed virologic failure with evidence of resistance to:
- •a) DTG in the P1093 parent study, or
- •b) ABC, DTG or 3TC (with the exception of M184V) in the P2019 parent study
- •2.Presence of any active Acquired Immunodeficiency Syndrome (AIDS) defining opportunistic infection.
- •3.Known =Grade 3 laboratory toxicities within 30 days prior to study entry (e.g. neutrophil count, hemoglobin, platelets, aspartate aminotransferase (AST), ALT, lipase, serum creatinine and total bilirubin). Repeat testing is allowed for eligibility determination. NOTE: =Grade 3 total bilirubin is allowable, if the subject is on ATV.
- •NOTE: Subjects with laboratory abnormalities considered unrelated to IP may be allowed to enter the study. Thus, if the laboratory abnormality persists upon repeat testing, the subject may be considered for study entry after consultation and approval of the study team.
- •4.Previous permanent discontinuation from IP in the parent study due to toxicity, intolerance, or pregnancy.
研究者
相似试验
已完成
不适用
A Phase I, open-label, single-sequence drug-drug interaction trial in subjects on stable methadone maintenance therapy, to investigate the potential interaction between TMC278 25 mg q.d. and methadone, at steady-state.AIDSHIV10047438NL-OMON32622TIBOTEC PHARMACEUTICALS LIMITED, EASTGATE VILLAGE, EASTGATE, LITTLE ISLAND, CO. CORK, IRELAND, In Nederland vertegenwoordigd door Janssen-Cilag B.V. afdeling GCO16
已完成
不适用
A phase 1, open-label, fixed-sequence, drug-drug interaction study of APX001 to evaluate the effects of CYP3A4 inhibition and pan-CYP induction in two parallel groups of healthy male and female subjectsFungal infectionsNL-OMON47992Amplyx Pharmaceuticals, Inc.36
已完成
不适用
A phase 1, open-label, fixed-sequence, drug-drug interaction study between multiple oral doses of Inarigivir Soproxil and a single oral dose of midazolam in healthy subjectsHepatitis BNL-OMON46790Spring Bank Pharmaceuticals, Inc.16
已完成
1 期
A BA/BE study to evaluate the safety, tolerability of endoxifen in healthy human subjectsCTRI/2009/091/000625ambda Therapeutic Research Ltd40
招募中
1 期
VLS-01-101: A study to assess Two formulations of VLS-01 (VLS-01 BU and VLS-01-IV) in healthy participantsTreatment resistant Depression (TRD)Mental Health - DepressionACTRN12622000851763Viridia Life Sciences Australia Pty Ltd48